Review




Structured Review

Servicebio Inc anti-β3 adrenergic receptor (β3 ar)
Anti β3 Adrenergic Receptor (β3 Ar), supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-β3 adrenergic receptor (β3 ar)/product/Servicebio Inc
Average 90 stars, based on 1 article reviews
anti-β3 adrenergic receptor (β3 ar) - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

90
Alomone Labs rabbit anti β 3 ar
Rabbit Anti β 3 Ar, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti β 3 ar/product/Alomone Labs
Average 90 stars, based on 1 article reviews
rabbit anti β 3 ar - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology β3 adrenergic receptor β3 ar
β3 Adrenergic Receptor β3 Ar, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β3 adrenergic receptor β3 ar/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
β3 adrenergic receptor β3 ar - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
Biorbyt β3 ar
Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.
β3 Ar, supplied by Biorbyt, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β3 ar/product/Biorbyt
Average 91 stars, based on 1 article reviews
β3 ar - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology β3 adrenergic receptor
Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.
β3 Adrenergic Receptor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β3 adrenergic receptor/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
β3 adrenergic receptor - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Servicebio Inc anti-β3 adrenergic receptor (β3 ar)
Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.
Anti β3 Adrenergic Receptor (β3 Ar), supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-β3 adrenergic receptor (β3 ar)/product/Servicebio Inc
Average 90 stars, based on 1 article reviews
anti-β3 adrenergic receptor (β3 ar) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology mouse anti β3 adrenergic receptor primary antibody
Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.
Mouse Anti β3 Adrenergic Receptor Primary Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti β3 adrenergic receptor primary antibody/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
mouse anti β3 adrenergic receptor primary antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology mouse anti β3 adrenergic receptor
Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.
Mouse Anti β3 Adrenergic Receptor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti β3 adrenergic receptor/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
mouse anti β3 adrenergic receptor - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.

Journal: Food Science and Human Wellness

Article Title: Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance

doi: 10.1016/j.fshw.2023.03.025

Figure Lengend Snippet: Fig. 1 Validation of ginsenoside F1 as a novel UCP1 activator. (a) Workflow for obtaining novel UCP1 activator. (b) Relative luciferase activity of HEK293T cells co-transfected with -2.5 kb UCP1-luciferase and renilla plasmid. Indicated ginsenosides (30 μmol/L) were added to HEK293T cells for 24 h, n = 3. (c) Structure of F1. (d) Optimization of ginsenoside F1 concentration, n = 5-6. (e) Ucp1 mRNA level was assessed in differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated by qRT-PCR, n = 4-5. (f) UCP1 protein expression was detected by western blotting in primary adipocytes and differentiated 3T3-L1 cells after ginsenoside F1 or PPT (100 μmol/L) treated. Data were presented as mean ± SD. The one-way ANOVA followed by the LSD post hoc test used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001 compared with ctrl group.

Article Snippet: The following primary antibodies were used: GAPDH (Servicebio, GB12002, 1:1 000), actin (BD biosciences, 612657, 1:5 000), UCP1 (Sigma, U6382, 1:1 000), PKA (Cell Signaling Technology, 4782S, 1:1000), p-PKA (Cell Signaling Technology, 5661T, 1:1000), p-CREB (Abcam, ab32096, 1:1 000), CREB (Cell Signaling Technology, 9197T, 1:1 000), PGC-1α (Abcam, ab54481, 1:1 000), PPARγ (Cell Signaling Technology, 2435T, 1:1 000), TGR5 (Novus Biologicals, NBP223669SS, 1:1 000), β3-AR (Biorbyt, orb221343, 1:1 000), p-IR (Cell signaling Technology, 3026, 1:1 000), IR (Cell signaling Technology , 3025, 1:1 000), Primary antibodies were incubated overnight at 4 °C.

Techniques: Biomarker Discovery, Luciferase, Activity Assay, Transfection, Plasmid Preparation, Concentration Assay, Quantitative RT-PCR, Expressing, Western Blot

Fig. 2 Ginsenoside F1 binds to β3-AR to enhance UCP1 expression via cAMP/PKA/CREB pathway. (a) Intracellular uptake of F1 in cells was analyzed using UPLC-MS. (b) 3T3-L1-derived adipocytes were treated with ginsenoside F1 (100 μmol/L) for 3 h, then analyzed PKA/CREB pathway using western blotting, n = 4. (c) PKA/CREB signaling was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using western blotting in the presence or absence of PKA inhibitor H 89. (d) The binding ability of F1 to β3-AR was evaluated in pull down assay. (e) Thermogenesis signaling was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using western blotting in the presence or absence of the β3-AR inhibitor SR 59230A. (f) Thermogenesis signaling was analyzed using western blotting. The 3T3-L1 adipocytes were transfected with negative control (NC) or β3-AR siRNAs 24 h prior to F1 treatment (100 μmol/L). (g) Mitochondria respiration was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) in the presence or absence of the β3-AR inhibitor SR 59230A, or treated with norepinephrine (NE) using Agilent Seahorse XFp Analyzer. (h) ATP content was detected in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using kits, n = 5. (i) UCP1 expression was analyzed in 3T3-L1 adipocytes treated with ginsenoside F1 (100 μmol/L) or different concentration of norepinephrine (NE) using western blotting. (j) Glucose uptake of the 3T3-L1 adipocytes (j1) and hepatocytes Hepa1-6 cells (j2) cultured in NE, ginsenoside F1 (100 μmol/L) or combination of NE and F1 (100 μmol/L), n = 4. (k) Glucose uptake of the 3T3-L1 adipocytes (k1) and hepatocytes Hepa1-6 cells (k2) cultured in NE, ginsenoside F1 (100 μmol/L) or combination of NE and F1 (100 μmol/L) with or without siRNA treatment. (l) Scheme for F1 increasing thermogenesis via UCP1 activation. Data were presented as mean ± SD. Two-way Student’s t-test (b-h) and one-way ANOVA followed by the LSD post hoc test (i-k) used for statistical analysis. #P < 0.05, ###P < 0.001 compared with ctrl group; *P < 0.05, **P < 0.01, ***P < 0.001 compared with F1 group.

Journal: Food Science and Human Wellness

Article Title: Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance

doi: 10.1016/j.fshw.2023.03.025

Figure Lengend Snippet: Fig. 2 Ginsenoside F1 binds to β3-AR to enhance UCP1 expression via cAMP/PKA/CREB pathway. (a) Intracellular uptake of F1 in cells was analyzed using UPLC-MS. (b) 3T3-L1-derived adipocytes were treated with ginsenoside F1 (100 μmol/L) for 3 h, then analyzed PKA/CREB pathway using western blotting, n = 4. (c) PKA/CREB signaling was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using western blotting in the presence or absence of PKA inhibitor H 89. (d) The binding ability of F1 to β3-AR was evaluated in pull down assay. (e) Thermogenesis signaling was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using western blotting in the presence or absence of the β3-AR inhibitor SR 59230A. (f) Thermogenesis signaling was analyzed using western blotting. The 3T3-L1 adipocytes were transfected with negative control (NC) or β3-AR siRNAs 24 h prior to F1 treatment (100 μmol/L). (g) Mitochondria respiration was analyzed in 3T3-L1 adipocytes treated with F1 (100 μmol/L) in the presence or absence of the β3-AR inhibitor SR 59230A, or treated with norepinephrine (NE) using Agilent Seahorse XFp Analyzer. (h) ATP content was detected in 3T3-L1 adipocytes treated with F1 (100 μmol/L) using kits, n = 5. (i) UCP1 expression was analyzed in 3T3-L1 adipocytes treated with ginsenoside F1 (100 μmol/L) or different concentration of norepinephrine (NE) using western blotting. (j) Glucose uptake of the 3T3-L1 adipocytes (j1) and hepatocytes Hepa1-6 cells (j2) cultured in NE, ginsenoside F1 (100 μmol/L) or combination of NE and F1 (100 μmol/L), n = 4. (k) Glucose uptake of the 3T3-L1 adipocytes (k1) and hepatocytes Hepa1-6 cells (k2) cultured in NE, ginsenoside F1 (100 μmol/L) or combination of NE and F1 (100 μmol/L) with or without siRNA treatment. (l) Scheme for F1 increasing thermogenesis via UCP1 activation. Data were presented as mean ± SD. Two-way Student’s t-test (b-h) and one-way ANOVA followed by the LSD post hoc test (i-k) used for statistical analysis. #P < 0.05, ###P < 0.001 compared with ctrl group; *P < 0.05, **P < 0.01, ***P < 0.001 compared with F1 group.

Article Snippet: The following primary antibodies were used: GAPDH (Servicebio, GB12002, 1:1 000), actin (BD biosciences, 612657, 1:5 000), UCP1 (Sigma, U6382, 1:1 000), PKA (Cell Signaling Technology, 4782S, 1:1000), p-PKA (Cell Signaling Technology, 5661T, 1:1000), p-CREB (Abcam, ab32096, 1:1 000), CREB (Cell Signaling Technology, 9197T, 1:1 000), PGC-1α (Abcam, ab54481, 1:1 000), PPARγ (Cell Signaling Technology, 2435T, 1:1 000), TGR5 (Novus Biologicals, NBP223669SS, 1:1 000), β3-AR (Biorbyt, orb221343, 1:1 000), p-IR (Cell signaling Technology, 3026, 1:1 000), IR (Cell signaling Technology , 3025, 1:1 000), Primary antibodies were incubated overnight at 4 °C.

Techniques: Expressing, Derivative Assay, Western Blot, Binding Assay, Pull Down Assay, Transfection, Negative Control, Concentration Assay, Cell Culture, Activation Assay